Safety, Tolerance and Efficacy of an Oral Nutritional Supplement in Chronic Heart Failure and Chronic Obstructive Pulmonary Disease Patients

Inclusion Criteria: * diagnosis of CHF or COPD * current body weight less than 6 months ago * BMI \>=20 and \<=30 kg/m2 * CHF: LVEF \>=45% measured within the past 6 months * symptom status equivalent to NYHA class II to IV * biochemical abnormalities for total cholesterol, serum uric acid, abnormal high CRP * on standard therapy of CHF including ACE inhibitors and beta blockers * COPD: symptom status equivalent to GOLD standard class II to IV * FEV1 \< 80% * FEV1/FEV \< 70% Exclusion Criteria: * significant oedema in the time of screening and randomisation * concomitant inflammatory diseases * active infections including HIV and AIDS * liver failure * chronic renal failure (sCr\>1.5mg/dL) or cardiac pacemaker * acute or chronic infections * insulin treated diabetes mellitus * patient with established diagnosis of cachexia * life expectancy of less than 6 months in the opinion of the investigator * medications that impair sex hormone synthesis, secretion or function * patients with psychiatric diseases * body weight loss \> 5% during the last 6 months or \> 10% during the last 10 months * suspected allergy to any component of the investigational product(s) * fish oil supplementation within 3 months prior to the study entry * taking vitamin supplements in doses greater than the Recommended Daily Allowances